Protecting the Next Generation: How to Minimize HIV Transmission from Mother to Child
"A comprehensive guide for expectant parents and healthcare providers on understanding and preventing perinatal HIV transmission."
For expectant parents, few things are more important than the health of their child. While rates of perinatal HIV transmission have dramatically decreased—by over 90% since the 1990s—it's vital to stay informed about how to minimize any remaining risk. This article provides a clear overview of current knowledge and best practices.
Approximately 8,500 women living with HIV give birth each year in the United States. Without intervention, HIV can be transmitted during pregnancy, labor, delivery, or breastfeeding. Understanding the factors that influence transmission is the first step in protecting your child.
This guide will walk you through the timing and risk factors of perinatal HIV transmission, offering insights into management recommendations and their implications for your care. We aim to empower you with the knowledge to make informed decisions and work effectively with your healthcare providers.
National Surveillance and Elimination Targets
In 2012, the Centers for Disease Control and Prevention published a Framework for Elimination of Perinatal Transmission of HIV in the United States in Pediatrics, setting goals of an incidence of fewer than one case of perinatal HIV per 100,000 live births and a perinatal transmission rate of less than one percent. The agency relies on National HIV Surveillance System (NHSS) data to monitor the numbers of perinatally acquired HIV cases against these targets. NHSS surveillance programs gather demographic characteristics such as sex, race/ethnicity, age, and place of diagnosis, along with transmission category (mode of exposure) and all test results indicative of HIV infection, including viral load and CD4 count and percent. These data systems inform HIV trend analysis and are used to prevent further HIV transmission.
Early Testing, Early Treatment, and a Sub-1% Target
The standard approach calls for HIV testing before pregnancy or as early as possible during each pregnancy so that antiretroviral therapy can be started promptly. When taken as prescribed throughout pregnancy, childbirth, and breastfeeding, antiretroviral therapy reduces the likelihood of perinatal transmission of HIV to less than one percent, which makes consistent adherence the central limitation of this method. The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission periodically updates the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States, revising sections to reflect new data and publications. Antepartum care guidelines complement this by outlining HIV disease evaluation and recommendations for HIV-related medical care during pregnancy.
Understanding HIV Transmission: Key Factors
Perinatal HIV transmission can occur at different times:
- In Utero: This accounts for a small percentage (5-10%) of transmissions. The placenta and amniotic fluid offer some protection, but transmission can occur via direct spread or ascending infection.
- Intrapartum: The majority of non-breastfeeding related transmissions happen during labor and delivery. Contact with maternal blood and cervicovaginal secretions are primary risks.
- Postpartum (Breastfeeding): Without HAART, there's a 10-15% transmission risk. HAART reduces this to less than 2%, but safe alternatives are readily available.
Viral Load, Postnatal Risk, and Evolving Evidence
A systematic review and meta-analysis in The Lancet, by Dugdale and colleagues and cited 43 times, estimates the effect of maternal viral load on perinatal and postnatal HIV transmission, finding a cumulative postnatal vertical transmission risk at 12 months of 2.9 percent among women on ART. Complementing it, a 2025 review by WR Short, cited 8 times, examines the intersection of pregnancy and HIV, focusing on birthing person and fetal health outcomes. Taken together, recent research underscores that viral load suppression is central to prevention but that a small postnatal risk persists even among treated women, informing updates to the perinatal HIV clinical guidelines.
Progress With Persisting Gaps
A 2025 review in Current HIV/AIDS Reports notes that perinatal transmission of HIV-1 has dramatically decreased over the past three decades in resource-rich settings such as the United States, largely due to the widespread availability of antiretroviral therapy. Yet the same review emphasizes that management challenges persist during pregnancy and explicitly highlights future directions for improving outcomes rather than treating the problem as solved. Its summary is that ART use during pregnancy has significantly reduced perinatal transmission, but ongoing research and collaboration remain vital to addressing the remaining challenges. These residual gaps - in monitoring, access, and evolving care needs - are where the prevention effort now concentrates.
Newer Agents With Pregnancy-Specific Evidence
An April 2, 2026 update to the US Perinatal Guidelines illustrates how the antiretroviral armamentarium is expanding during pregnancy: pharmacokinetic and safety data are now available in pregnancy and lactation for the long-acting capsid inhibitor lenacapavir, and this information is detailed in the Lenacapavir drug section of the guideline. The availability of such data for a newer agent marks a shift in how treatment options are compared during pregnancy, moving beyond general-population efficacy toward evidence collected specifically in pregnant and lactating individuals. The update also welcomes clinical feedback on the latest revisions to the Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States.
Working Towards Elimination
Thanks to advances in detection and treatment, we've dramatically lowered perinatal HIV transmission rates. The CDC's goal is to eliminate it entirely.
Consensus Guidance and a Shared Clinical Vocabulary
In an annual update in 2025, the US Department of Health and Human Services published an expert consensus guideline titled "Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States," referred to as the US Perinatal Guidelines. Experts also emphasize precise terminology: vertical transmission refers to HIV transmission to infants during the perinatal period, either through pregnancy, delivery, or postpartum through lactation (breast/chest feeding). Reviews in this area primarily discuss and refer to pregnant and lactating individuals, reflecting an evolving and inclusive clinical vocabulary. Together these sources show that authoritative consensus guidance and careful terminology are foundational to both clinical practice and research on perinatal HIV.
Next-Generation Prevention on the Horizon
Newer antiretroviral agents and formulations, along with advances in testing and monitoring, are expected to continue narrowing the already small residual risk of mother-to-child transmission. Ongoing research into longer-acting and injectable options, more sensitive point-of-care viral load tools, and care models that reach people earlier in pregnancy could bring elimination goals within closer reach. Realizing any of these advances in pregnancy and lactation will still depend on collecting dedicated human data of the kind recent guideline updates have begun to provide, so these projections should be read as the field's direction rather than confirmed outcomes.
Access, Equity, and Health System Barriers
Sustaining progress against mother-to-child HIV transmission ultimately depends on health systems reaching every pregnant person with timely testing, treatment, and follow-up, regardless of income, geography, or insurance status. Even where effective medical tools exist, fragmented care and missed prenatal visits can keep residual transmission risk higher among some communities, making equity inseparable from the elimination goal. Public health surveillance and coordinated, multidisciplinary models of care are widely regarded as essential to closing these gaps. These points are offered as general context rather than as findings from a single cited study.
Real Cases, Real Residual Risk
A case reported in the Journal of Pediatric Health Care underscores three key themes: the small but real residual risk of perinatal transmission even with reported suppression, the vulnerability created by lapses in maternal monitoring, and the importance of integrated, multidisciplinary care. Alongside that case-level lesson, a retrospective cohort study of mother-infant pairs in a high HIV prevalence area of the United States evaluated the uptake of perinatal HIV preventive interventions by risk of transmission. The pairing of individual case reporting with cohort data illustrates both the human stakes of missed monitoring and the measurable gaps in intervention uptake that prevention programs must still address.
To achieve this, we need continued research into the best antiretroviral regimens and obstetric practices. Addressing socioeconomic factors that create barriers to care is also essential.
Ultimately, staying informed, proactive, and working closely with your healthcare team are the best ways to protect your child and contribute to a future free of perinatal HIV transmission.